Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
129 hedge funds and large institutions have $332M invested in Aerie Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 38 increasing their positions, 41 reducing their positions, and 35 closing their positions.
299% more call options, than puts
Call options by funds: $842K | Put options by funds: $211K
7% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 41
6% less funds holding
Funds holding: 137 → 129 (-8)
20% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 35
36% less capital invested
Capital invested by funds: $522M → $332M (-$190M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JG
Jefferies Group
New York
|
+$24.9M |
| 2 |
Morgan Stanley
New York
|
+$19M |
| 3 |
DM
Deerfield Management
New York
|
+$18M |
| 4 |
Millennium Management
New York
|
+$9.31M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$4.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$11.4M |
| 2 |
William Blair Investment Management
Chicago,
Illinois
|
-$11.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$10.4M |
| 4 |
ClearBridge Investments
New York
|
-$9.93M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$6.49M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
V
151
Veritable
Wilmington,
Delaware
| – | -$136K | -11,968 | Closed |
|
|
MC
152
Maverick Capital
Dallas,
Texas
| – | -$77K | -6,723 | Closed |
|
|
GRP
153
Global Retirement Partners
San Rafael,
California
| – | -$19K | -1,661 | Closed |
|
|
HPC
154
HM Payson & Co
Portland,
Maine
| – | -$14K | -1,189 | Closed |
|
|
SSB
155
Sandy Spring Bank
Olney,
Maryland
| – | -$14K | -1,189 | Closed |
|
|
PCM
156
Penserra Capital Management
Orinda,
California
| – | -$12K | -1,080 | Closed |
|
157
Rockefeller Capital Management
New York
| – | -$7K | -655 | Closed |
|
|
LC
158
Lindbrook Capital
Calabasas,
California
| – | -$4K | -387 | Closed |
|
159
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$4K | -376 | Closed |
|
|
PA
160
Parallel Advisors
San Francisco,
California
| – | -$3.16K | -302 | Closed |
|
|
FHA
161
First Horizon Advisors
Memphis,
Tennessee
| – | -$2K | -257 | Closed |
|
|
TWA
162
TCI Wealth Advisors
Tucson,
Arizona
| – | -$2K | -192 | Closed |
|
|
S
163
SignatureFD
Atlanta,
Georgia
| – | -$1K | -67 | Closed |
|
AERI Hedge Fund Activity: Q4 2021 in Review
129 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q4 2021, worth a combined $332M — down 36% from $522M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of AERI and 28 opened new positions — a net loss of 7 holders — while 41 trimmed existing stakes and 38 added.
The largest buyer was Jefferies Group, opening a new position worth an estimated $24.9M. The largest seller was PFM Health Sciences, cutting an estimated $11.4M.
- 129 institutional investors held Aerie Pharmaceuticals (AERI) as of Q4 2021, down from 137 in Q3 2021.
- Funds reported $332M of Aerie Pharmaceuticals stock for Q4 2021, down 36% quarter-over-quarter.
- 28 funds opened new Aerie Pharmaceuticals positions in Q4 2021 and 35 closed out, a net change of -7 holders.
- The largest Aerie Pharmaceuticals buyer in Q4 2021 was Jefferies Group, an estimated $24.9M added.
- The largest Aerie Pharmaceuticals seller in Q4 2021 was PFM Health Sciences, an estimated $11.4M sold.
Based on aggregated 13F filings for Q4 2021.